此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

扩展性治疗计划评估SkinTE在Wagner 1级糖尿病足溃疡治疗中的应用

2026年11月2日 更新者:PolarityTE

评估SkinTE治疗Wagner 1级糖尿病足溃疡的扩大可及性项目

The purpose of this EAP is to provide access to SkinTE® for patients with Wagner I Diabetic Foot Ulcers (DFUs). SkinTE® is an autologous investigational product created from a healthy full-thickness skin harvest. SkinTE is applied directly to the wound with the goal of promoting healing.

In addition to providing treatment, the program will collect safety and efficacy data. This data will help us understand the potential risks and benefits of SkinTE® when used in a real-world setting. PolarityBio® provides research funding to the study site to support data collection.

研究概览

研究类型

扩展访问

扩展访问类型

  • 中型人口

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不适用

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. ≥18 years of age
  2. Subjects are medically optimized with a documented history of Type I or Type II Diabetes Mellitus requiring insulin and/or oral therapy.
  3. Presence of a DFU Wagner 1 grade wound on any aspect of the foot, provided that if the malleolus is involved, not more than 50% of the wound is above the mid-point of the medial malleolus. Note: Index Ulcer must maintain Wagner grade 1 from screening to harvest procedure.
  4. Index ulcer (i.e., current episode of ulceration) has been present for ≥ four weeks (≥ 28 days) prior to the initial screening visit.
  5. If other wound(s) are present on the same foot, they must be more than 2 cm distant from the index ulcer.
  6. Ulcer size between 1.0 cm² and 25 cm² post-debridement at screening and day of Harvest, which may occur 3 to 30 days after screening.
  7. Adequate circulation to the affected foot documented by a dorsal transcutaneous oxygen measurement (TCOM) or skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) of ≥ 0.7 and ≤ 1.2 or Arterial Doppler with a minimum of biphasic flow or Toe Brachial Index (TBI) ≥ 0.75 using the affected study extremity within 30 days of the screening visit.
  8. Index ulcer and/or index ulcer limb may have had prior infection(s), but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines PEDIS Grade level 1.
  9. The subject can comply with study visits, wound management, and follow-up regimen.
  10. The treating investigator has determined that no suitable alternative therapy is available to adequately address the patient's medical needs.
  11. Based on the treating investigator's clinical judgment and the severity of the patient's condition, the patient has the potential to derive meaningful benefits from the use of SkinTE.
  12. Females of childbearing potential must agree to use effective methods of contraception (birth control pills, barriers, or abstinence) (Screening through End of Study (EOS) and undergo pregnancy tests.
  13. Negative pregnancy test for females of childbearing potential (e.g., not post- menopausal for at least one year or surgically sterile).
  14. Properly obtained written informed consent.
  15. Subjects who previously received SkinTE as part of a prior SkinTE-related trial may be considered for participation, provided a new index ulcer is selected for treatment on the contralateral limb and sponsor approval is granted.

Exclusion Criteria:

  1. Participation in another investigational drug or therapeutic device trial within 30 days prior to screening.
  2. Use of prohibited medication(s) as defined in this protocol.
  3. Presence of diabetes with poor metabolic control, defined as a documented historical HbA1c ≥12.0% within 90 days prior to screening.
  4. Subjects with a history of more than two weeks of treatment with immunosuppressants (including systemic corticosteroids > 10mg prednisone (or equivalent) daily dose), or cytotoxic chemotherapy prior to screening.
  5. Index ulcer treated within 30 days of screening with prohibited treatment as defined in this protocol.
  6. Subjects with presence of gangrene, unstable ischemia, or active Charcot's foot.
  7. Subjects with recent lower extremity revascularization within ≤30 days of screening.
  8. Based on the treating investigators clinical judgement there is no suspicion of malignancy in the index ulcer.
  9. History of osteomyelitis, cellulitis, or other soft tissue infections involving the index ulcer within 30 days of screening.
  10. Subjects with exposed internal fixation on the same limb as the index ulcer. [Note: External fixation is allowed if deemed stable by principal investigator.]
  11. Active infection of the index ulcer (as defined by IDSA PEDIS Grade 1 guidelines) of the affected limb.
  12. History of radiation therapy on the affected limb.
  13. Subject is pregnant or breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

2025年10月27日

首先提交符合 QC 标准的

2025年10月29日

首次发布 (实际的)

2025年10月30日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • PolarityBio EAP - DFU 01

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅